Insider Transactions in Q2 2021 at Steris PLC (STE)
Insider Transaction List (Q2 2021)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 02
2021
|
Richard C Breeden Director |
BUY
Grant, award, or other acquisition
|
Direct |
160
+0.46%
|
-
|
Jun 02
2021
|
Christopher S Holland Director |
BUY
Grant, award, or other acquisition
|
Direct |
7
+9.46%
|
-
|
Jun 02
2021
|
Andrew Xilas SVP and GM, Dental |
BUY
Grant, award, or other acquisition
|
Direct |
232
+50.0%
|
-
|
Jun 02
2021
|
Daniel A Carestio President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,056
+16.48%
|
-
|
Jun 02
2021
|
John Adam Zangerle Sr. VP, Gen Counsel, and Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
3,276
+9.78%
|
-
|
Jun 02
2021
|
Cary L Majors SVP and President, Healthcare |
BUY
Grant, award, or other acquisition
|
Direct |
1,964
+11.61%
|
-
|
Jun 02
2021
|
Karen L Burton VP & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
784
+11.5%
|
-
|
Jun 02
2021
|
Mary Clare Fraser SVP & Chief HRO |
BUY
Grant, award, or other acquisition
|
Direct |
1,836
+27.81%
|
-
|
Jun 02
2021
|
Renato Tamaro V.P. & Corporate Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
576
+9.68%
|
-
|
Jun 02
2021
|
Julia Madsen Sr. VP and GM, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+19.73%
|
-
|
Jun 02
2021
|
Michael J Tokich Sr. Vice Pres., CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,292
+4.76%
|
-
|
Jun 01
2021
|
Daniel A Carestio President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,677
-6.37%
|
$315,276
$188.43 P/Share
|
Jun 01
2021
|
John Adam Zangerle Sr. VP, Gen Counsel, and Sec. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,945
-6.73%
|
$365,660
$188.43 P/Share
|
Jun 01
2021
|
Cary L Majors SVP and President, Healthcare |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,129
-14.08%
|
$400,252
$188.43 P/Share
|
Jun 01
2021
|
Karen L Burton VP & CAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
897
-14.6%
|
$168,636
$188.43 P/Share
|
Jun 01
2021
|
Mary Clare Fraser SVP & Chief HRO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
234
-7.4%
|
$43,992
$188.43 P/Share
|
Jun 01
2021
|
Renato Tamaro V.P. & Corporate Treasurer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
133
-2.7%
|
$25,004
$188.43 P/Share
|
Jun 01
2021
|
Julia Madsen Sr. VP and GM, Life Sciences |
SELL
Sale (or disposition) back to the issuer
|
Direct |
224
-1.23%
|
$42,112
$188.43 P/Share
|
Jun 01
2021
|
Michael J Tokich Sr. Vice Pres., CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,946
-4.27%
|
$365,848
$188.43 P/Share
|
May 27
2021
|
Richard C Breeden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,121
+8.23%
|
$96,751
$31.61 P/Share
|
May 25
2021
|
Cynthia L Feldmann Director |
SELL
Open market or private sale
|
Direct |
4,000
-73.89%
|
$760,000
$190.84 P/Share
|
May 25
2021
|
Cynthia L Feldmann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+42.49%
|
$268,000
$67.73 P/Share
|
May 21
2021
|
Jacqueline B Kosecoff Director |
SELL
Open market or private sale
|
Direct |
3,121
-100.0%
|
$599,232
$192.59 P/Share
|
May 21
2021
|
Jacqueline B Kosecoff Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,121
+50.0%
|
$96,751
$31.61 P/Share
|
Apr 23
2021
|
Julia Madsen Sr. VP and GM, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,000
-17.73%
|
$215,000
$215.0 P/Share
|
Apr 23
2021
|
Julia Madsen Sr. VP and GM, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+15.06%
|
$69,000
$69.72 P/Share
|
Apr 20
2021
|
Julia Madsen Sr. VP and GM, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,000
-17.73%
|
$210,000
$210.0 P/Share
|
Apr 20
2021
|
Julia Madsen Sr. VP and GM, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+15.06%
|
$69,000
$69.72 P/Share
|